Chimerix, Inc. (NASDAQ:CMRX - Get Free Report) shares passed above its fifty day moving average during trading on Monday . The stock has a fifty day moving average of $1.82 and traded as high as $3.80. Chimerix shares last traded at $3.54, with a volume of 1,915,300 shares changing hands.
Analyst Ratings Changes
A number of analysts have commented on the stock. HC Wainwright reiterated a "buy" rating and issued a $11.00 price objective on shares of Chimerix in a report on Monday, December 30th. Wedbush reaffirmed an "outperform" rating and issued a $6.00 price target on shares of Chimerix in a report on Tuesday, December 10th.
Get Our Latest Analysis on Chimerix
Chimerix Price Performance
The business has a fifty day moving average of $1.82 and a 200 day moving average of $1.22. The stock has a market capitalization of $329.17 million, a price-to-earnings ratio of -3.89 and a beta of 0.36.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently modified their holdings of the company. Marshall Wace LLP purchased a new stake in Chimerix during the 2nd quarter worth about $137,000. Valeo Financial Advisors LLC lifted its position in shares of Chimerix by 566.9% during the 3rd quarter. Valeo Financial Advisors LLC now owns 81,766 shares of the biopharmaceutical company's stock worth $76,000 after purchasing an additional 69,505 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. raised its stake in Chimerix by 66.8% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 344,712 shares of the biopharmaceutical company's stock valued at $321,000 after buying an additional 138,098 shares in the last quarter. 45.42% of the stock is currently owned by hedge funds and other institutional investors.
About Chimerix
(
Get Free Report)
Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.
Further Reading
Before you consider Chimerix, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Chimerix wasn't on the list.
While Chimerix currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
